Actively Recruiting
Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy
Led by Nantes University Hospital · Updated on 2026-04-16
60
Participants Needed
1
Research Sites
116 weeks
Total Duration
On this page
Sponsors
N
Nantes University Hospital
Lead Sponsor
I
Institut National de la Santé Et de la Recherche Médicale, France
Collaborating Sponsor
AI-Summary
What this Trial Is About
There are 2 possible treatments for the treatment of Acute Myelogenous Leukemia (AML), high-risk myelodysplastic syndromes (HR-MDS) or chronic myelomonocytic leukemia (CMML): intensive curative chemotherapy , and for over-aged or co-morbid patients , non-intensive palliative chemotherapy with a hypomethylating agent (Azacytidine) associated or not with venetoclax. Pro-inflammatory cytokines and in particular IL-6 (Interleukin 6) seem to play a key role in the chemoresistance of solid cancers and AML : it would be associated with a poor prognosis of AML , would promote the proliferation of leukemic blasts , and would promote the progression of MDS to AML . In AML treated with intensive chemotherapy, researchers demonstrated that a particular kinetic profile of the FLT3 ligand and IL6 at day 22 could very significantly predict the survival of patients with AML . It therefore seems interesting to study the plasma cytokine profiles in patients with AML, HR-MDS or CMML treated non-intensively, and to see if researchers observe the same prognostic correlation as during intensive chemotherapy.
CONDITIONS
Official Title
Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age �3E=18 years
- Diagnosis of AML, high-risk myelodysplastic syndrome, or chronic myelomonocytic leukemia in first line or relapse
- Receiving a hypomethylating agent with or without another drug, or combined with venetoclax
- Patient has agreed to participate and signed informed consent and biocollection consent
You will not qualify if you...
- No social security or any other insurance coverage
- Pregnant or unable to use contraception if fertile
- Breastfeeding women
- Minors under 18 years
- Adults under guardianship, curatorship, or legal protection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nantes University Hospital
Nantes, Loire-Atlantique, France, 44093
Actively Recruiting
Research Team
A
Alice GARNIER, PH
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here